LanzaTech Global (LNZA) 10-Q9 May 242024 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover	3 Months Ended
Cover	Mar. 31, 2024 shares
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-40282
Entity Registrant Name	LanzaTech Global, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	92-2018969
Entity Address, Address Line One	8045 Lamon Avenue
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Skokie
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60077
City Area Code	847
Local Phone Number	324-2400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	197,725,477
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001843724
Amendment Flag	false
Document Fiscal Year Focus	2024
Common stock
Document Information [Line Items]
Title of 12(b) Security	Common stock
Trading Symbol	LNZA
Security Exchange Name	NASDAQ
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	LNZAW
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 56,747	$ 75,585
Held-to-maturity investment securities	34,819	45,159
Trade and other receivables, net of allowance	10,689	11,157
Contract assets	29,159	28,238
Other current assets	15,490	12,561
Total current assets	146,904	172,700
Property, plant and equipment, net	22,613	22,823
Right-of-use assets	17,813	18,309
Equity method investment	6,354	7,066
Equity security investment	14,990	14,990
Other non-current assets	5,822	5,736
Total assets	214,496	241,624
Current liabilities:
Accounts payable	2,072	4,060
Other accrued liabilities	6,187	7,316
Warrants	4,012	7,614
Contract liabilities	3,814	3,198
Accrued salaries and wages	5,110	5,468
Current lease liabilities	128	126
Total current liabilities	21,323	27,782
Non-current lease liabilities	19,329	19,816
Non-current contract liabilities	7,438	8,233
Fixed Maturity Consideration	7,604	7,228
FPA Put Option liability	50,192	37,523
Brookfield SAFE liability	15,475	25,150
Other long-term liabilities	1,319	1,421
Total liabilities	122,680	127,153
Shareholders’ Equity
Common stock, $0.0001 par value; 400,000,000 and 400,000,000 shares authorized, 197,725,477 and 196,642,451 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	19	19
Additional paid-in capital	946,771	943,960
Accumulated other comprehensive income	2,406	2,364
Accumulated deficit	(857,380)	(831,872)
Total shareholders’ equity	91,816	114,471
Total liabilities and shareholders' equity	$ 214,496	$ 241,624

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	400,000,000	400,000,000
Common shares, shares issued (in shares)	197,725,477	196,642,451
Common shares, shares outstanding (in shares)	197,725,477	196,642,451

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Total revenue	$ 10,244	$ 9,646
Cost and operating expenses:
Cost of revenue from collaborative arrangements (exclusive of depreciation shown below)	(796)	(407)
Cost of revenue from related party transactions (exclusive of depreciation shown below)	(57)	(41)
Research and development expense	(17,061)	(16,286)
Depreciation expense	(1,530)	(1,257)
Selling, general and administrative expense	(11,037)	(16,835)
Total cost and operating expenses	(36,398)	(42,168)
Loss from operations	(26,154)	(32,522)
Other income (expense):
Interest income, net	1,148	214
Other income (expense), net	179	(30,396)
Total other income (expense), net	1,327	(30,182)
Loss before income taxes	(24,827)	(62,704)
Income tax expense	0	0
Loss from equity method investees, net	(681)	(608)
Net loss	(25,508)	(63,312)
Other comprehensive loss:
Foreign currency translation adjustments	42	(49)
Comprehensive loss	(25,466)	(63,361)
Unpaid cumulative dividends on preferred stock	0	(4,117)
Net loss allocated to common shareholders	$ (25,508)	$ (67,429)
Net loss per common share, basic (in dollars per share)	$ (0.13)	$ (0.58)
Net loss per common share, diluted (in dollars per share)	$ (0.13)	$ (0.58)
Weighted-average number of common shares outstanding - basic (in shares)	196,974,508	116,530,963
Weighted-average number of common shares outstanding - diluted (in shares)	196,974,508	116,530,963
Collaborative Arrangement
Revenues [Abstract]
Total revenue	$ 2,223	$ 1,088
Service and Grants \| Nonrelated Party
Revenues [Abstract]
Total revenue	6,250	7,585
Tangible Products
Cost and operating expenses:
Cost of revenue from contracts with customers (exclusive of depreciation shown below)	(919)	0
Tangible Products \| Nonrelated Party
Revenues [Abstract]
Total revenue	863	0
Service
Cost and operating expenses:
Cost of revenue from contracts with customers (exclusive of depreciation shown below)	(4,998)	(7,342)
Service \| Related Party
Revenues [Abstract]
Total revenue	$ 908	$ 973

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY /DEFICIT - USD ($) $ in Thousands	Total	Previously Reported	Revision of Prior Period, Adjustment	Common Stock Outstanding	Common Stock Outstanding Previously Reported	Common Stock Outstanding Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income Previously Reported
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022				10,422,051	2,382,358	8,039,693
Beginning balance at Dec. 31, 2022	$ (428,722)	$ (428,722)	$ 0	$ 1	$ 0	$ 1	$ 24,782	$ 24,783	$ (1)	$ (456,245)	$ (456,245)	$ 2,740	$ 2,740
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,505						3,505
RSA vesting (in shares)				2,535,825
Repurchase of equity instruments (in shares)				(771,141)
Repurchase of equity instruments	(7,650)						(7,650)
Net loss	(63,312)									(63,312)
Issuance of common stock upon exercise of options (in shares)				470,843
Issuance of common stock upon exercise of options	746						746
In-kind payment of preferred dividend	(241,529)									(241,529)
Conversion of preferred stock into common stock (in shares)				153,895,644
Conversion of preferred stock into common stock	728,050			$ 15			728,035
Recapitalization, net of transaction expenses (Note 3) (in shares)				28,898,374
Recapitalization, net of transaction expenses (Note 3)	236,973			$ 3			236,970
Forward Purchase Agreement prepayment	(60,547)						(60,547)
Reclassification of warrants to equity	1,800						1,800
Foreign currency translation	(49)											(49)
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2023				195,451,596
Ending balance at Mar. 31, 2023	$ 169,265			$ 19			927,641			(761,086)		2,691
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631
Increase (Decrease) in Temporary Equity [Roll Forward]
Exercise of a warrant, Series C and D Preferred Stock (in shares)	594,309
Exercise of a warrant, Series C and D Preferred Stock	$ 5,890
In-kind payment of preferred dividend	$ 241,529
Conversion of preferred stock into common stock (in shares)	(129,742,702)
Conversion of preferred stock into common stock	$ (728,050)
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2023	0
Ending balance, temporary equity at Mar. 31, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2023	196,642,451			196,642,451
Beginning balance at Dec. 31, 2023	$ 114,471			$ 19			943,960			(831,872)		2,364
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	2,625						2,625
Repurchase of equity instruments	(48)						(48)
Net loss	$ (25,508)									(25,508)
Issuance of common stock upon exercise of options (in shares)	162,000			1,083,026
Issuance of common stock upon exercise of options	$ 234						234
Foreign currency translation	$ 42											42
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2024	197,725,477			197,725,477
Ending balance at Mar. 31, 2024	$ 91,816			$ 19			$ 946,771			$ (857,380)		$ 2,406

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities:
Net loss	$ (25,508)	$ (63,312)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	2,529	3,505
Gain on change in fair value of SAFE and warrant liabilities	(13,277)	(20,979)
Loss on change in fair value of the FPA Put Option and the Fixed Maturity Consideration liabilities	13,045	51,109
Provision for losses on trade and other receivables	0	800
Depreciation of property, plant and equipment	1,530	1,257
Amortization of discount on debt security investment	(360)	0
Non-cash lease expense	496	532
Non-cash recognition of licensing revenue	(641)	(553)
Loss from equity method investees, net	681	608
Net foreign exchange gain	(224)	(171)
Changes in operating assets and liabilities:
Accounts receivable, net	645	1,618
Contract assets	(1,029)	(408)
Accrued interest on debt investment	(177)	0
Other assets	(3,012)	(8,593)
Accounts payable and accrued salaries and wages	(2,207)	1,692
Contract liabilities	616	(60)
Operating lease liabilities	(485)	(667)
Other liabilities	(911)	(188)
Net cash used in operating activities	(28,289)	(33,810)
Cash Flows From Investing Activities:
Purchase of property, plant and equipment	(1,480)	(1,367)
Purchase of debt securities	0	(49,103)
Proceeds from maturity of debt securities	10,700	0
Net cash provided by/ (used in) investing activities	9,220	(50,470)
Cash Flows From Financing Activities:
Proceeds from issue of equity instruments of the Company	234	746
Proceeds from the Business Combination and PIPE, net of transaction expenses (Note 3)	0	213,381
Forward Purchase Agreement prepayment	0	(60,096)
Repurchase of equity instruments of the Company	(48)	(7,650)
Net cash provided by financing activities	186	146,381
Net decrease in cash, cash equivalents and restricted cash	(18,883)	62,101
Cash, cash equivalents and restricted cash at beginning of period	76,284	83,710
Effects of currency translation on cash, cash equivalents and restricted cash	48	(25)
Cash, cash equivalents and restricted cash at end of period	57,449	145,786
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of property, plant and equipment under accounts payable	141	234
Reclassification of capitalized costs related to the business combination to equity	0	1,514
Cashless conversion of warrants on preferred shares	0	5,890
Recognition of public and private warrant liabilities in the Business Combination	0	4,624
Reclassification of AM SAFE warrant to equity	0	1,800
Conversion of AM SAFE liability into common stock	0	29,730
Conversion of Legacy LanzaTech NZ, Inc. preferred stock and in-kind dividend into common stock	$ 0	$ 722,160

Description of the Business

Description of the Business	3 Months Ended
Description of the Business	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II (“AMCI”) prior to February 8, 2023 (the “Closing Date”) was incorporated as a Delaware corporation on January 28, 2021. On March 8, 2022, LanzaTech NZ, Inc. ("Legacy LanzaTech") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI and AMCI Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). On February 8, 2023, Legacy LanzaTech completed its business combination with AMCI by which the Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech continuing as the surviving corporation and as a wholly owned subsidiary of AMCI (the “Business Combination”). The reporting entity is LanzaTech Global, Inc. and its subsidiaries (collectively referred to herein as “the Company”, "LanzaTech", “we”, “us”, “our”). For more information on the Business Combination, see Note 3 - Reverse Recapitalization . The Company is headquartered in Skokie, Illinois, USA. The Company is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The Company’s customers leverage its proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol. The Company performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government entities. The Company also purchases low carbon chemicals produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart. We have also been developing the capabilities to produce single cell protein as a primary product from our gas fermentation platform. As of March 31, 2024, licensees of the Company’s technology operate four commercial-scale waste-to-gas ethanol plants in China, one plant in India, and one plant in Belgium with others currently in development in various countries, compared to three commercial scale waste-to-gas ethanol plants in China as of March 31, 2023. As a result of the Business Combination, the Company’s common stock trades under the ticker symbol “LNZA” and its Public Warrants trade under the ticker symbol “LNZAW” on the Nasdaq Stock Market. Prior to the consummation of the Business Combination, the Company’s common shares were listed on Nasdaq Stock Market under the symbol “AMCI” and the Public Warrants were listed on the Nasdaq Stock Market under the symbol “AMCI-W”. Unless otherwise indicated, amounts in these financial statements are presented in thousands, except for share and per share amounts.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. The condensed consolidated financial statements include the accounts of LanzaTech Global, Inc. and its wholly-owned consolidated subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in LanzaTech's Annual Report on Form 10-K for the year ended December 31, 2023. The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances: • Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company; • Legacy LanzaTech’s existing senior management team comprise senior management of the Company; • The operations of the Company primarily represent operations of Legacy LanzaTech; and • In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets. For more information on the Business Combination, see Note 3 - Reverse Recapitalization . Significant Accounting Policies Our significant accounting policies are included in Note 2 of the Notes to our Audited Consolidated Financial Statements included in our Annual Report. Revision of previously issued financial statements In connection with the preparation of the Company’s consolidated financial statements for the year ended December 31, 2023, the Company determined it should have classified the Forward Purchase Agreement prepayment as a cash outflow from financing activities within the consolidated statement of cash flows, instead of a cash outflow from investing activities as previously reported. The Company has corrected this classification for the three months ended March 31, 2023 within the consolidated statement of cash flows. The company determined the incorrect classification was not material to the previously filed quarterly report. There is no impact to the Company’s condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of changes in redeemable convertible preferred stock and shareholders’ equity/deficit or cash flows from operating activities. Going Concern The accompanying consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $56,747, short-term held-to-maturity debt investments of $34,819 and an accumulated deficit of $(857,380) as of March 31, 2024 and cash outflows from operations of $(28,289) and a net loss of $(25,508) for the three months ended March 31, 2024. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (“ACM”) and Vellar Opportunity Fund SPV LLC - Series 10 (“Vellar”) in relation to the Forward Purchase Agreement (see below). The Company has historically funded its operations through issuances of equity securities and debt financing. Based on the Company’s financial position as of the date the condensed consolidated financial statements were issued, the Company projects that it will be able to cover its liquidity needs for the next twelve months. In addition, on May 9, 2024, the Company entered into the ATM Agreements (as defined in Note 15 - Subsequent Events ), which may provide additional liquidity as described in Note 15 - Subsequent Events. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of equity awards granted to both employees and non-employees, valuation of common stock prior to the close of the Business Combination, revenue recognized over time, AM SAFE and Brookfield SAFE obligations, AM SAFE warrants, the Forward Purchase Agreement and the Private Placement Warrants. The Company uses the percentage of completion for the input method to recognize revenue over time for certain contracts with customers. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance. Most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to the Revenue Recognition section in Note 2 - Summary of Significant Accounting Policies hereunder. Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of March 31, 2024 and December 31, 2023, the Company had $56,747 and $75,585 of cash and cash equivalents, respectively. Restricted Cash The Company is required to maintain a cash deposit with a bank which consists of collateral on certain travel and expense programs maintained by the bank. The following represents a reconciliation of Cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of March 31, 2024 and December 31, 2023. As of March 31, 2024 December 31, 2023 Cash and cash equivalents $ 56,747 $ 75,585 Restricted cash (presented within Other current assets) 702 699 Cash, cash equivalents and restricted cash $ 57,449 $ 76,284 Forward Purchase Agreement On February 3, 2023, the Company entered into a Forward Purchase Agreement (“FPA”) with ACM. On the same date, ACM partially assigned its rights under the FPA to Vellar. ACM and Vellar are together referred to as the “Purchasers”. Pursuant to the Forward Purchase Agreement, the Purchasers obtained 5,916,514 common shares (“Recycled Shares”) on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60,096 was funded by the use of AMCI trust account proceeds as a partial prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption 3 years from the date of the Business Combination (“Maturity Date”). The Maturity Date may be accelerated, at the Purchasers discretion, if the Company share price trades below $3.00 per share for any 50 trading days during a 60 day consecutive trading-day period or the Company is delisted. On any date following the Business Combination, the Purchasers also have the option to early terminate the arrangement in whole or in part by providing optional early termination notice to the Company (the “Optional Early Termination”). For those shares early terminated (the “Terminated Shares”), the Purchasers will owe the Company an amount equal to the Terminated Shares times the Redemption Price, which may be reduced in the case of certain dilutive events (“Reset Price”). At the Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”). In addition to the Maturity Consideration, on the Maturity Date, the Company shall pay to the Purchasers an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5,079 (the “Share Consideration”). If the Purchasers were to utilize their Optional Early Termination to terminate the FPA early in its entirety, neither the Maturity Consideration nor the Share Consideration would be due to the Purchasers. The Purchasers’ Optional Early Termination economically results in the prepaid forward contract being akin to a written put option with the Purchaser’s right to sell all or a portion of the 5,916,514 common shares to the Company. The Company is entitled over the 36-month maturity period to either a return of the prepayment or the underlying shares, which the Purchasers will determine at their sole discretion. The FPA consists of three freestanding financial instruments which are accounted for as follows: 1) The total prepayment of $60,547 (“Prepayment Amount”), which is accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares and sale of shares to the Purchasers pursuant to a subscription agreement. 2) The “FPA Put Option” which includes both the in-substance written put option and the portion of the Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”). The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The initial fair value of the FPA Put Option and subsequent changes in fair value of the FPA Put Option are recorded within Other income (expense), net on the condensed consolidated statements of operations and comprehensive loss. 3) The “Fixed Maturity Consideration,” which includes the minimum portion of the Maturity Consideration (the “Minimum Maturity Consideration”), calculated as 7,500,000 less 5,916,513 multiplied by $2.00 or $3,167, and the Share Consideration. Both the Minimum Maturity Consideration and the Share Consideration are considered to be free-standing debt instruments and as both will be paid on the same terms and at the same time, these are accounted for together. The Company has elected to measure these using the FVO under ASC 825, Financial Instruments (“ASC 825”). The Fixed Maturity Consideration is recorded as a long-term liability on the condensed consolidated balance sheets. The initial fair value of the Fixed Maturity Consideration and subsequent changes in fair value of the Fixed Maturity Consideration are recorded within Other income (expense), net on the condensed consolidated statements of operations and comprehensive loss. Revenue Recognition The Company recognizes revenue from exchange transactions in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to biorefining (formerly known as carbon capture and transformation) which includes feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are: (1) joint development and contract research activities to develop and optimize novel biocatalysts, related processes and technologies, and (2) supply of chemical building blocks for sustainable products produced using the Company’s proprietary technologies (referred to as CarbonSmart). Revenue is measured based on the consideration specified in a contract with a customer. The Company records taxes collected from customers and remitted to governmental authorities on a net basis. The Company’s payment terms are between 30-60 days and can vary by customer type and products offered. Management has evaluated the terms of the Company’s arrangements and determined that they do not contain significant financing components. Biorefining The Company provides feasibility studies and basic design and engineering services used for detailed design, procurement, and construction of commercial plants that utilize the Company’s technologies, along with the sale of microbes and media. The services provided are recognized as a performance obligation satisfied over time. Revenue is recognized using the cost-to-cost input method for certain engineering services, or the percentage of completion method as performance obligations are satisfied. Revenue for the sale of microbes and media is at a point in time, depending on when control transfers to the customer. The Company licenses intellectual property to generate recurring revenue, in the case of running royalties, or one-time revenue, in the case of fixed consideration royalties, when its customers deploy the Company’s technology in their biorefining plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later. Grants received to perform engineering services, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue as the qualifying costs related to the grant have been incurred. Joint Development and Contract Research The Company performs R&D services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. The Company engages in two main types of R&D services – joint development agreements, and contract research, including projects with the U.S. Department of Energy and other US or foreign government agencies. Such services are recognized as a performance obligation satisfied over time. Revenue is recognized based on milestone completion, when payments are contingent upon the achievement of such milestones, or based on percentage-completion method when enforceable rights to payment exist. When no milestones or phases are clearly defined, management has determined that the cost incurred, input method, is an appropriate measure of progress towards complete satisfaction of the performance obligations under ASC 606 , and estimates its variable consideration under the expected value method. Revenue is not recognized in advance of customer acceptance of a milestone when such acceptance is contractually required. Payments for R&D services with no contractual payments are not due from customers until a technical report is submitted; therefore, a contract asset is recognized at milestone completion but prior to the submission of a technical report. The contract asset represents the Company’s right to consideration for the services performed at milestone completion. Occasionally, customers provide payments in advance of the Company providing services which creates a contract liability for the Company. The contract liability represents the Company's obligation to provide services to a customer. CarbonSmart The Company purchases ethanol from the customers who have deployed our proprietary technologies in their biorefining plants and sells it and its derivatives as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from sales of CarbonSmart products in the condensed consolidated statements of operations and comprehensive loss. Collaboration Arrangements The Company has certain partnership agreements that are within the scope of ASC 808, Collaborative Arrangements , which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transaction under the collaborative arrangements is determined based on the nature of the contractual terms of the arrangement, along with the nature of the operations of the participants. The Company’s collaborative agreements generally include a provision of R&D services related to novel technologies and biocatalysts. Amounts received for these services are classified as Revenue from collaborative arrangements in the consolidated statements of operations and comprehensive loss. The Company's R&D services are a major part of the Company's ongoing operations and therefore ASC 606 is applied to recognize revenue. Cost of Revenues The Company’s R&D, engineering, and other direct costs of services and goods related to revenue agreements with customers, related parties, and collaborative partners represent cost of revenue. Costs include both internal and third-party fixed and variable costs and include materials, supplies, labor, and fringe benefits. Research and Development We incur costs associated with various R&D activities and expense them as incurred. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access; Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities; and Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement , approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the warrant liability. Concentration of Credit Risk and Other Risks and Uncertainties Revenue generated from the Company’s customers and grant providers from outside of the United States for the three months ended March 31, 2024 and 2023 was approximately 56% and 62%, respectively. As of March 31, 2024 and December 31, 2023, approximately 45% and 49%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers and grant providers located outside the United States. As of March 31, 2024 and December 31, 2023, the value of property, plant, and equipment outside the United States was immaterial. The Company’s revenue by geographic region based on the contracting entities’ location is presented in Note 5 - Revenues . Our largest contracting entities represent 10% or greater of revenue and were as follows for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, 2024 2023 Customer A 18 % — % Customer B 11 % 30 % Customer C 11 % 4 % Customer D 10 % 1 % Customer E 8 % 10 % Customer F 7 % 13 %

Reverse Recapitalization

Reverse Recapitalization	3 Months Ended
Reverse Recapitalization	Mar. 31, 2024
Reverse Recapitalization [Abstract]
Reverse Recapitalization	Reverse Recapitalization On February 8, 2023, Legacy LanzaTech and AMCI consummated the merger contemplated by the Merger Agreement (see Note 1 - Description of the Business ). Immediately following the Business Combination, there were 196,222,737 shares of common stock outstanding with a par value of $0.0001. Additionally, there were outstanding warrants to purchase 12,574,200 shares of common stock. As discussed in Note 2 - Summary of Significant Accounting Policies , the Business Combination was accounted for as a reverse recapitalization in accordance with US GAAP. Under this method, while AMCI was the legal acquirer, it has been treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of pre-combination Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of pre-combination Legacy LanzaTech. Reported shares and earnings per share available to holders of the Company’s common stock and preferred shares, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Business Combination (approximately one pre-combination Legacy LanzaTech share to 4.3747 of the Company’s shares). Upon closing of the Business Combination, the shareholders of AMCI, including AMCI founders, were issued 10,398,374 shares of common stock of the Company. In connection with the closing, holders of 8,351,626 shares of common stock of AMCI were redeemed at a price per share of approximately $10.16. In connection with the Closing, 18,500,000 shares of common stock of the Company were issued to PIPE investors. 15,500,000 of those shares were issued at a price per share of $10.00. The remaining 3,000,000 shares were issued upon conversion of the AM SAFE liability. The Company incurred $7,223 in transaction costs relating to the Business Combination and recorded those costs against Additional paid-in capital in the condensed consolidated balance sheets. The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were: Shares Percentage Legacy LanzaTech shares 167,324,363 85.3 % Public stockholders 10,398,374 5.3 % PIPE shares 18,500,000 9.4 % Total 196,222,737 100 % The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statements of cash flows for the period ended March 31, 2023: Recapitalization Cash - AMCI trust account 1 $ 64,090 Cash - PIPE financing 155,000 Less: Transaction costs allocated to equity (5,709) Effect of the Business Combination and PIPE financing $ 213,381 __________________ (1) The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses. The following table reconciles the elements of the Business Combination and PIPE financing to the change in Additional paid-in capital on the condensed consolidated statement of changes in redeemable preferred stock and shareholders' equity/deficit: Recapitalization Cash - AMCI trust account $ 64,090 Public Warrants and Private Placement Warrants recorded on the Closing Date (4,624) Cash - PIPE financing 155,000 Conversion of the AM SAFE 29,730 Transaction costs allocated to equity (7,223) $ 236,973 Less: par value of shares held by PIPE investors and public stockholders (3) Total additional paid-in capital from recapitalization $ 236,970

Net Loss Per Share

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common stock equivalents of the Company, including equity-classified share-based compensation, the Brookfield SAFE, and warrants, to the extent dilutive. The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts): Three Months Ended March 31, 2024 2023 Numerator: Net loss for basic and diluted earnings per common share $ (25,508) $ (63,312) Unpaid cumulative dividends on preferred stock — (4,117) Net loss allocated to common shareholders $ (25,508) $ (67,429) Denominator: Weighted-average shares used in calculating net loss per share, basic and diluted 196,974,508 116,530,963 Net loss per common share, basic and diluted (1) $ (0.13) $ (0.58) __________________ (1) In periods in which the Company reports a net loss, all common stock equivalents are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on loss per share. As of March 31, 2024 and 2023, common stock equivalents not included in the computation of loss per share because their effect would be antidilutive include the following: March 31, 2024 2023 Options 16,167,460 14,355,066 RSUs 5,944,771 — Brookfield SAFE 5,000,000 5,000,000 Warrants 16,657,686 16,657,686 Total 43,769,917 36,012,752

Revenues

Revenues	3 Months Ended
Revenues	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenues	Revenues Disaggregated Revenue The following table presents disaggregated revenue in the following categories (in thousands): Three Months Ended March 31, 2024 2023 Contract Types: Licensing $ 580 $ 553 Engineering and other services 4,456 5,801 Biorefining revenue $ 5,036 $ 6,354 Joint development agreements 2,872 2,036 Contract research 1,473 1,256 Joint development and contract research revenue $ 4,345 $ 3,292 CarbonSmart product 863 — Total Revenue $ 10,244 $ 9,646 The following table presents revenue from partners in collaborative arrangements and from grant contributions which are included in the table above as follows (in thousands): Three Months Ended March 31, 2024 2023 Revenue from partners in collaborative agreements included in the Joint development agreements above 2,223 $ 1,088 Revenue from grant contributions included in Engineering and other services above 1,156 3,067 The following table presents disaggregation of the Company’s revenues by customer location for the three months ended March 31, 2024 and 2023 (in thousands): Three Months Ended March 31, 2024 2023 North America $ 4,458 $ 4,232 Europe, Middle East, Africa (EMEA) 4,580 4,711 Asia 1,206 50 Australia — 653 Total Revenue $ 10,244 $ 9,646 Contract balances The following table provides changes in contract assets and liabilities (in thousands): Current Contract Assets Current Contract Liabilities Non-current Contract Liabilities Balance as of December 31, 2023 $ 28,238 $ 3,198 $ 8,233 Additions to unbilled accounts receivable 10,120 — — Increases due to cash received — 3,208 — Unbilled accounts receivable recognized in trade receivables (9,091) — — Decrease on revaluation on currency (108) (1) (123) Reclassification from long-term to short-term — 672 (672) Reclassification to revenue as a result of performance obligations satisfied — (3,263) — Balance as of March 31, 2024 $ 29,159 $ 3,814 $ 7,438 The increase in contract assets was mostly due to unbilled accounts receivable resulting from revenue recorded under contracts with customers and grants where the Company performed engineering and other services, and primarily relates to contracts with government entities. The decrease in contract liabilities was primarily due to the recognition of revenue during the period related to advance payments previously received by the Company for engineering and other services contracts with customers. As of March 31, 2024 and December 31, 2023 the Company had $10,689 and $11,157, respectively, of billed accounts receivable, net of allowance. The contract liability balance comprises unconditional payments received from the Company’s customers prior to the satisfaction of the related performance obligations. Such amounts are anticipated to be recorded as revenues when services are performed in subsequent periods. The Company expects to recognize the amounts classified as current contract liabilities in revenue within one year or less and those classified as non-current within two to three years. Remaining performance obligations Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue that will be recognized as revenue in future periods. Transaction price allocated to remaining performance obligations is influenced by several factors, including the length of the contract term compared to the research term and the existence of customer specific acceptance rights. Remaining performance obligations consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Current $ 3,814 $ 3,198 Non-current 7,438 8,233 Total $ 11,252 $ 11,431

Investments

Investments	3 Months Ended
Investments	Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments HTM Debt Securities Held to maturity (“HTM”) debt securities are comprised of U.S. Treasury bills and notes, Yankee debt securities, and corporate debt securities. HTM debt securities are classified as short-term or long-term based upon the contractual maturity of the underlying investment. March 31, 2024 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Accrued Interest Short-term US Treasury bills and notes 10,661 0 $ (1) $ 10,660 $ 45 Corporate debt securities 21,158 4 (25) 21,137 311 Yankee debt securities 3,000 — — 3,000 87 Total debt securities due within a year $ 34,819 $ 4 $ (26) $ 34,797 $ 443 Total HTM Debt Securities 34,819 4 (26) 34,797 443 December 31, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Accrued Interest Short-term US Treasury bills and notes 20,423 6 $ — $ 20,429 $ 14 Corporate debt securities 21,736 14 (33) 21,717 209 Yankee debt securities 3,000 — (8) 2,992 43 Total debt securities due within a year $ 45,159 $ 20 $ (41) $ 45,138 $ 266 Total HTM Debt Securities 45,159 20 (41) 45,138 266 The Company regularly reviews held-to-maturity securities for declines in fair values that are determined to be credit related. As of December 31, 2023 and March 31, 2024, the Company did not have an allowance for credit losses related to HTM securities. Equity investments The Company’s equity investments consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Equity Method Investment in LanzaJet $ 6,354 $ 7,066 Equity Security Investment in SGLT 14,990 14,990 Total Investment $ 21,344 $ 22,056 LanzaJet On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (“Original Interest”) of LanzaJet, Inc. (“LanzaJet”) in connection with an investment agreement (“Investment Agreement”). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the three months ended March 31, 2024 and March 31, 2023, the Company recognized revenue from this arrangement of $580 and $553 respectively, net of intra-entity profit elimination and has associated deferred revenue of $4,704 and $5,375, as of March 31, 2024 and December 31, 2023, respectively. Intra-entity profits related to this arrangement are $92 and $118 for the three months ended March 31, 2024 and 2023, respectively. Intra-entity profits are amortized over a 15-year period through 2034. Between February 1, 2021 and April 4, 2021, LanzaJet closed two additional rounds of investment which reduced the Original Interest to approximately 23%. In connection with the LanzaJet Note Purchase Agreement as described in Note 13 - Related Party Transactions , LanzaJet issued warrants that are exercisable for $0.01 by the holder when the related funds are drawn by LanzaJet. The warrants held by LanzaTech and other lenders meet the accounting criteria for in-substance common stock at the time the related note commitment is drawn by LanzaJet and the warrants become exercisable. As of March 31, 2024, LanzaTech’s ownership was diluted to 22.89% because LanzaTech received proportionally fewer warrants than the other investors. The Company recorded a gain on dilution of $77 in the three months ended March 31, 2024. LanzaTech’s ownership is subject to further dilution to 22.38% if LanzaJet draws additional funds committed in the LanzaJet Note Purchase Agreement and the remaining warrants are exercisable by the holders. Under the LanzaJet Investment Agreement, certain other LanzaJet shareholders agreed to make an additional cash investment following the achievement of certain development milestones relating to the demonstration facility. If made, these additional investments would fund the development and operation of commercial facilities that would sublicense the relevant fuel production technology from LanzaJet. Upon the closing of each of the first three of these additional investments and no later than the sublicensing of the relevant facility, LanzaTech has a right to receive up to an aggregate of 45 million additional LanzaJet shares for no additional consideration. To date, these shares have not been issued. The carrying value of our equity method investment in LanzaJet as of March 31, 2024 and December 31, 2023 was approximately $3,400 less than our proportionate share of our equity method investees’ book values, for both periods. The basis differences are largely the result of a difference in the timing of recognition of variable consideration to which we may become entitled in exchange for our contribution of intellectual property to LanzaJet. The variable consideration we may receive will be in the form of additional ownership interests and the majority of the basis difference will be reversed in connection with recognition of that variable consideration. In connection with a sublicense agreement to LanzaJet under our license agreement with Battelle Memorial Institute (“Battelle”), LanzaTech remains responsible for any failure by LanzaJet to pay royalties due to Battelle. The fair value of LanzaTech’s obligation under this guarantee was immaterial as of March 31, 2024 and December 31, 2023. SGLT On September 28, 2011, the Company contributed RMB 25,800 (approx. $4,000) in intellectual property in exchange for 30% of the registered capital of Beijing Shougang LanzaTech Technology Co., LTD (“SGLT”). Since then, the Company’s interest in SGLT’s registered capital decreased to approximately 9.31% as a result of the investment by new investors. The Company accounts for its investment in equity securities of SGLT using the alternative measurement principals as permitted under ASC 321, Investments - Equity Securities, because SGLT's fair value is not readily determinable. For the three months ended March 31, 2024 , there was no change in the recorded amount of the investment in SGLT. As of March 31, 2024 and December 31, 2023, there were no impairments of equity investments. During the three months ended March 31, 2024 and 2023, the Company received no dividends from equity investments. See Note 13 - Related Party Transactions

SAFE

SAFE	3 Months Ended
SAFE	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SAFE	SAFE Brookfield SAFE On October 2, 2022, the Company entered into a SAFE with Brookfield (the "Brookfield SAFE"). Under the Brookfield SAFE, the Company agreed to issue to Brookfield the right to certain shares of its capital stock, in exchange for the payment of $50,000 (the “Initial Purchase Amount”). The Brookfield SAFE is legal form debt. Management has elected to apply the Fair Value Option ("FVO") under ASC 825, Financial Instruments . As the Brookfield SAFE is accounted for under the FVO, the Brookfield SAFE is classified as a mark-to-market liability On the fifth anniversary of the Brookfield SAFE, LanzaTech is required to repay in cash the Initial Purchase Amount less any Non-Repayable Amount (the “Remaining Amount”), as well as interest on such Remaining Amount in the high single digits, compounded annually. For each $50,000 of aggregate equity funding required for qualifying projects presented to Brookfield in accordance with the Brookfield Framework Agreement (discussed below), the Remaining Amount will be reduced by $5,000 (such cumulative reductions the “Non-Repayable Amount”) and converted into LanzaTech Shares at $10.00 per share, which was the share price paid by the PIPE investors in the Business Combination. Interest on the corresponding amount will be forgiven. Each project presented must meet certain criteria in order to be considered a qualifying project. Additionally, Brookfield may, at any time at its option, convert all or a portion of the Initial Purchase Amount less any amount that has already been converted or repaid into shares of LanzaTech capital stock at the same $10.00 per share price. The Brookfield SAFE has not yet converted as a qualifying financing has not yet occurred and no qualified project investments have been presented to Brookfield as of March 31, 2024. As of March 31, 2024 and December 31, 2023, the fair value of the Brookfield SAFE was $15,475 and $25,150 respectively and was recorded within Brookfield SAFE liability on the condensed consolidated balance sheets. Brookfield Framework Agreement On October 2, 2022, LanzaTech entered into a framework agreement with Brookfield (the “Brookfield Framework Agreement”). Under such agreement, LanzaTech agreed to exclusively offer Brookfield the opportunity to acquire or invest in certain projects to construct commercial production facilities employing carbon capture and transformation technology in the U.S., the European Union, the United Kingdom, Canada or Mexico for which LanzaTech is solely or jointly responsible for obtaining or providing equity financing, subject to certain exceptions. LanzaTech agreed to present Brookfield with projects that over the term of the agreement that require equity funding of at least $500,000 in the aggregate. With respect to projects acquired by Brookfield, LanzaTech is entitled to a percentage of free cash flow generated by such projects determined in accordance with a hurdle-based return waterfall. Brookfield has no obligation under the Brookfield Framework Agreement to invest in any of the projects. There have been no investments in projects as of March 31, 2024 or 2023.

Warrants

Warrants	3 Months Ended
Warrants	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants	Warrants Shortfall Warrants On March 27, 2023, the Company issued an aggregate of 2,073,486 warrants to ACM and 2,010,000 warrants to Vellar pursuant to the Forward Purchase Agreement (collectively, the “Shortfall Warrants”), as further described in Note 2 - Summary of Significant Accounting Policies . Each Shortfall Warrant entitles the registered holder to purchase one share of common stock at a price of $10.00 per share, subject to adjustment in the event that the Company sells, grants or otherwise issues common stock or common stock equivalents at an effective price less than the then current exercise price of the Shortfall Warrants, at any time commencing on or after March 27, 2023. A holder of a Shortfall Warrant may exercise such warrants on a cashless basis. The Shortfall Warrants expire on the fifth anniversary of their issuance. On the issuance date, the Shortfall Warrants met the definition of a derivative but did not qualify for the exception from derivative accounting under the indexation guidance and therefore met the criteria for liability classification under ASC 815. The fair value of the Shortfall Warrants as of March 31, 2023 was $5,104. On May 13, 2023, the Company amended the Shortfall Warrant agreement. Under the amended agreement, the Shortfall Warrants meet the requirements for equity classification under ASC 815-40. Consequently, the Company recorded a gain of $2,042 as of the date of the amendment to reflect the fair value of $3,063 at the date of the amendment through Other income (expense), net on the condensed consolidated statements of operations and comprehensive loss and reclassified the Shortfall Warrants to Additional paid-in capital on the condensed consolidated balance sheets. Public Warrants and Private Placement Warrants As part of AMCI’s initial public offering (“IPO”), AMCI issued warrants to third-party investors. Each public warrant entitles the holder to purchase one share of the Company’s common stock at an exercise price of $11.50 per share (the “Public Warrants”). Simultaneously with the closing of the IPO, AMCI completed the private sale of warrants. Each private sale warrant allows the holder to purchase one share of the Company’s common stock at $11.50 per share. Additionally, prior to the consummation of the Business Combination, AMCI issued warrants for the settlement of a working capital loan. The working capital warrants have the same terms as the private sale of warrants issued at the IPO. Warrants sold in the private sale at the IPO and the warrants issued to convert the working capital loan are collectively referred to as the “Private Placement Warrants”. On the Closing Date and as of March 31, 2024 , 7,499,924 Public Warrants and 4,774,276 Private Placement Warrants remained outstanding. These warrants expire on the fifth anniversary of the Business Combination or earlier upon redemption or liquidation and are exercisable commencing 30 days after the Business Combination, provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Once the Public Warrants become exercisable, the Company may redeem the outstanding warrants: a. in whole and not in part; b. at a price of $0.01 per warrant; c. upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and d. if, and only if, the closing price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three trading days before we send the notice of redemption to the warrant holders. The Company additionally has the ability to redeem the Public Warrants at the option of the Company when the price of common stock exceeds $10.00 per share at a price of $0.10 per warrant. In this scenario, warrant holders may choose to exercise their warrants on a cashless basis during the minimum 30-day notice period, and receive common stock in exchange for their warrants at a rate based on fair value of the common stock and the proximity to the expiration date of the warrants. As long as the Private Placement warrants are held by AMCI Sponsor II LLC (the “Sponsor”) or its permitted transferees, they are not redeemable by LanzaTech. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by LanzaTech in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. The Public Warrants and Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognized the warrant instruments as liabilities at fair value as of the Closing Date, with an offsetting entry to Additional paid-in capital and adjusts the carrying value of the instruments to fair value through Other income (expense), net on the condensed consolidated statements of operations and comprehensive loss at each reporting period until they are exercised. The Public Warrants and Private Placement Warrants are presented within Warrants on the condensed consolidated balance sheets .

Forward Purchase Agreement

Forward Purchase Agreement	3 Months Ended
Forward Purchase Agreement	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Forward Purchase Agreement	Forward Purchase Agreement The FPA consists of the Prepayment Amount, the FPA Put Option and the Fixed Maturity Consideration. The Prepayment Amount of $60,547 is presented as a reduction to Additional paid-in capital in our condensed consolidated balance sheets. The value of the FPA Put Option represents the economics of the written put option, inclusive of the Variable Maturity Consideration, and is valued at $50,192 as of March 31, 2024. The Fixed Maturity Consideration is valued at $7,604 as of March 31, 2024. This represents the fair value of the Share Consideration and Fixed Maturity Consideration and is measured in accordance with the FVO. Expensed transaction costs, representing the stock acquisition fees, in the amount of $451 are recorded in Other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period ended March 31, 2023.

Fair Value

Fair Value	3 Months Ended
Fair Value	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value	Fair Value The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of March 31, 2024 and December 31, 2023 (in thousands): Fair Value Measurement as of March 31, 2024 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 39,298 $ — $ — $ 39,298 Total assets $ 39,298 $ — $ — $ 39,298 Liabilities: FPA Put Option liability $ — $ — $ 50,192 $ 50,192 Fixed Maturity Consideration — — 7,604 7,604 Brookfield SAFE liability — — 15,475 15,475 Private placement warrants — — 2,148 2,148 Public warrants 1,864 — — 1,864 Total liabilities $ 1,864 $ — $ 75,419 $ 77,283 Fair Value Measurement as of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 28,058 $ — $ — $ 28,058 Liabilities: FPA Put Option liability — — 37,523 37,523 Fixed Maturity Consideration — — 7,228 7,228 Brookfield SAFE liability — — 25,150 25,150 Private placement warrants — — 3,915 3,915 Public warrants 3,699 — — 3,699 Total Liabilities $ 3,699 $ — $ 73,816 $ 77,515 Forward Purchase Agreement The fair value upon issuance of the FPA (both the FPA Put Option liability and Fixed Maturity Consideration) and subsequent changes in fair value are included in Other income (expense), net in the condensed consolidated statements of operations and comprehensive loss in the corresponding period. The fair value of the FPA was estimated using a Monte-Carlo Simulation in a risk-neutral framework. Specifically, the future stock price is simulated assuming a Geometric Brownian Motion (“GBM”). For each simulated path, the forward purchase value is calculated based on the contractual terms and then discounted back to present. Finally, the value of the forward is calculated as the average present value over all simulated paths. The Fixed Maturity Consideration was also valued as part of this model as the timing of the payment of the Fixed Maturity Consideration may be accelerated if the Maturity Date is accelerated. The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of March 31, 2024 and December 31, 2023: March 31, 2024 December 31, 2023 Stock price $ 3.10 $ 5.03 Term (in years) 1.86 2.11 Expected volatility 50.0 % 50.0 % Risk-free interest rate 4.60 % 4.16 % Expected dividend yield — % — % Brookfield SAFE The Brookfield SAFE is legal form debt that the Company has elected to measure using the FVO under ASC 825. As of March 31, 2024, no part of the Brookfield SAFE has converted to Company common shares as a qualifying financing had not yet occurred and no project investments were presented. There were no cash flows associated with the Brookfield SAFE in the three months ended March 31, 2024. As of March 31, 2024, the Company expects to present sufficient projects to Brookfield to result in the Brookfield SAFE being automatically converted into shares. Since the liquidity price is not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield receives is fixed. Based on this expectation, the value of the Brookfield SAFE is equal to the Brookfield SAFE's as-converted value, which is the initial purchase amount, divided by the liquidity price, multiplied by the stock price, resulting in an estimated fair value of $15,475 recorded on the consolidated balance sheet. Significant inputs for Level 3 Brookfield SAFE measurement at March 31, 2024 and December 31, 2023 are as follows: March 31, 2024 December 31, 2023 Initial purchase amount $ 50,000 $ 50,000 Liquidity price $ 10.00 $ 10.00 Stock price $ 3.10 $ 5.03 Public Warrants and Private Placement Warrants For the Public Warrants, the Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value. Changes in fair value are recorded in Other income (expense), net within the condensed consolidated statements of operations and comprehensive loss. The company recognized decreases in the fair value of the liability of $1,835 and $286 during the three months ended March 31, 2024 and 2023, respectively. The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model. For the three months ended March 31, 2024, the Company recognized a decrease in the fair value of $1,766. For the three months ended March 31, 2023, the Company recognized an increase in the fair value of liabilities of approximately $477. Changes in fair value are recorded on the condensed consolidated statements of operations and comprehensive loss within Other income (expense), net. The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of March 31, 2024 and December 31, 2023: March 31, 2024 December 31, 2023 Stock price $ 3.10 $ 5.03 Exercise price $ 11.50 $ 11.50 Term (in years) 3.86 4.11 Expected volatility 57.5 % 45.0 % Risk-free interest rate 4.32 % 3.92 % Expected dividend yield — % — % The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands): FPA Put Option Fixed Maturity Consideration Brookfield SAFE Private placement warrants Balance as of January 1, 2024 $ (37,523) $ (7,228) $ (25,150) $ (3,914) (Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss (12,669) (376) 9,675 1,766 Balance as of March 31, 2024 $ (50,192) $ (7,604) $ (15,475) $ (2,148) FPA Put Option Fixed Maturity Consideration Shortfall Warrants Warrants on Preferred Shares AM SAFE liability AM SAFE warrant Brookfield SAFE Private placement warrants Balance as of January 1, 2023 $ — $ — $ — $ (2,119) $ (28,986) $ (1,989) $ (50,000) $ — Recognized as a result of the Business Combination — — — — — — — (2,148) (Loss) gain recognized in other expense, net on the consolidated statement of operations and comprehensive loss (44,593) (6,967) (5,104) (3,770) (744) 189 30,600 (477) Conversion of warrants to preferred shares — — — 5,889 — — — — Conversion of SAFE liability to equity classification — — — — 29,730 — — — Reclassification of warrant to equity — — — — 1,800 — — Balance as of March 31, 2023 $ (44,593) $ (6,967) $ (5,104) $ — $ — $ — $ (19,400) $ (2,625)

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to federal and state income taxes in the United States, as well as income taxes in foreign jurisdictions in which it conducts business. The Company does not provide for federal income taxes on the undistributed earnings of its foreign subsidiaries as such earnings are reinvested indefinitely. The Company and its foreign subsidiaries have historically been loss generating entities that have resulted in no excess earnings to consider for repatriation and accordingly there are no deferred income taxes recognized for the three months ended March 31, 2024 and 2023. The Company recorded an income tax expense of $0 for the three months ended March 31, 2024 and 2023, representing an effective tax rate of 0%. The difference between the U.S. federal statutory rate of 21% and the Company's effective tax rate in the three months ended March 31, 2024 and 2023 is primarily due to a full valuation allowance related to the Company's U.S. and foreign deferred tax assets. The Company reassesses the need for a valuation allowance on a quarterly basis. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made. The Company conducts business in multiple jurisdictions within and outside the United States. Consequently, the Company is subject to periodic income tax examinations by domestic and foreign income tax authorities. The Company is subject to audits for tax years 2017 and onward for federal purposes. There are tax years which remain subject to examination in various other state and foreign jurisdictions that are not material to the Company's financial statements. The Organization for Economic Co-operation and Development (OECD) has a framework to implement a global minimum corporate tax of 15% for companies with global revenues and profits above certain thresholds (referred to as Pillar 2), with certain aspects of Pillar 2 effective January 1, 2024 and other aspects effective January 1, 2025. While it is uncertain whether the U.S. will enact legislation to adopt Pillar 2, certain countries in which we operate have adopted legislation, and other countries are in the process of introducing legislation to implement Pillar 2. We do not anticipate Pillar 2 to have material impacts on our effective tax rate, financial position or cash flows during the current year.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
Share-Based Compensation	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation The Company adopted the LanzaTech 2023 Long-Term Incentive Plan (the “LTIP”) in conjunction with the closing of the Business Combination. The LTIP provides for grants of a variety of awards to employees, directors, and other service providers to the Company, including, but not limited to stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock-based awards or cash incentives. Prior to the effective date of the closing of the Business Combination, the Company granted awards under the LanzaTech NZ Inc. 2013 Stock Plan, the LanzaTech NZ Inc. 2015 Stock Plan, and the LanzaTech NZ, Inc. 2019 Stock Plan, (collectively, the “Prior Stock Plans”). Equity Classified Awards: RSUs Under the LTIP, the Company has granted two types of RSUs: time-based RSUs, and market-based RSUs. Time-based RSUs granted to employees and other service providers (other than directors) are generally subject to a three-year annual pro-rata vesting schedule whereby the awards generally vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to grantee’s continued service through each vesting date. However, vesting will accelerate in certain circumstances (e.g., retirement, death, disability, or a qualified termination in connection with a change in control). Time-based RSUs granted to directors are subject to a one-year vesting schedule and the full award vests on the first anniversary of the vesting commencement date, subject to the director’s continued service through the vesting date. However, vesting will accelerate in certain circumstances (e.g., removal in connection with a change in control). The market-based RSUs have both a time-based and a market-based vesting component. Both components must be met for the award to vest. The market-based RSUs are subject to a three-year annual pro-rata vesting schedule whereby the awards generally vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to grantee’s continued service through each vesting date. The market-based vesting component is satisfied if on any date during the period beginning on the 151st date following the vesting commencement date and ending on the fifth anniversary of the vesting commencement date, the average closing price of a share of the Company’s common stock, equals or exceeds $11.50, determined using the closing share price from the 20 trading days preceding such determination date. A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table: Time-based RSUs Market-based RSUs Shares (in thousands) Weighted Average Grant Date Fair Value Shares Weighted Average Grant Date Fair Value January 1, 2024 3,155 3.51 3,930 $ 1.69 Vested (1,033) 3.44 — — Cancelled/forfeited (107) 3.45 — — March 31, 2024 2,015 3.54 3,930 $ 1.69 The Company recorded compensation expense related to the time-based RSUs of $791 for the three months ended March 31, 2024. Unrecognized compensation costs as of March 31, 2024 were $6,760 and will be recognized over a weighted average of 1.96 years. The Company recorded compensation expense related to the market-based RSUs of $727 for the three months ended March 31, 2024. Unrecognized compensation costs as of March 31, 2024 were 2,471 and will be recognized over a weighted average of 1.47 years. Stock Options In accordance with the LTIP and Prior Stock Plans, grantees have also been granted stock options to purchase common shares. The exercise price of each stock option was no less than the fair market value price of the Company’s common shares determined as of the date of grant. The stock options generally vest over the course of two Stock option awards outstanding as of March 31, 2024 and changes during the period ended March 31, 2024 were as follows: Shares subject to option (thousands) Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (thousands) Outstanding at January 1, 2024 16,412 $ 1.96 Vested and expecting to vest at January 1, 2024 16,412 1.96 Exercisable at January 1, 2024 10,869 $ 1.49 Granted — — Exercised (162) 1.45 Cancelled/forfeited (83) 1.45 Outstanding at March 31, 2024 16,167 $ 1.97 5.92 $ 20,605 Vested and expecting to vest at March 31, 2024 16,167 1.97 5.92 20,605 Exercisable at March 31, 2024 12,351 $ 1.66 5.21 $ 18,539 The Company recorded compensation expense related to the options of $1,107 and $764 for the three months ended ended March 31, 2024 and 2023. Unrecognized compensation costs as of March 31, 2024 were $7,205 and will be recognized over a weighted average of 1.85 years. Restricted Stock Awards (“RSAs”) Under the Prior Stock Plans, the Company granted RSAs which become eligible to vest upon the satisfaction of a time-based service condition. However, in order to vest, a liquidity event, defined as acquisition, asset transfer, or initial listing, must occur within 10 years from the grant date. Upon a liquidity event, if the participant’s service has not terminated, the entire RSA award vests in full, whether or not previously eligible for vesting. If the participant’s service has terminated and the participant has satisfied the time-based service condition, the RSAs that are outstanding and eligible for vesting immediately vest in full upon liquidity event. The time-based service requirements of the RSAs have a maximum term of three years from the date of grant. The Business Combination constituted a “liquidity event” which caused the vesting of all such outstanding, unvested RSAs. The vesting of the RSAs resulted in compensation expense of $2,741 for the 3 months ended March 31, 2023. In connection with the vesting of these RSAs, certain holders of the RSAs surrendered 771,141 shares in a withhold to cover transaction to fund the payment of applicable tax withholding on their behalf by the Company. This resulted in a total cash payment of $7,650 by the Company to the Internal Revenue Service for the applicable tax withholding associated with this vesting event. Liability-Classified Awards Phantom RSUs Under a phantom equity sub-plan of the LTIP, certain non-US employees of the Company were provided with Phantom RSUs that can only be settled in cash and are therefore recorded as a liability. The Phantom RSUs have a graded vesting schedule and vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to the employee meeting the requisite service requirements. Grantees are entitled to receive a cash payment equal to the fair market value of a share multiplied by the number of vested Phantom RSUs as of the applicable vesting date. Phantom SARs Under a phantom equity sub-plan of the LTIP, certain non-US employees of the company were provided with Phantom SARs that can only be settled in cash and are therefore recorded as a liability. The Phantom SARs have a graded vesting schedule and vest in three equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to the employee meeting the requisite service requirements. Phantom SARs expire 10 years after the grant date and entitle the grantee to receive a cash payment upon exercise of the award equal to the excess of the fair market value of a share on the date of exercise over the exercise price multiplied by the number of SARs exercised.

Related Party Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions As of March 31, 2024 and December 31, 2023, the Company has an equity ownership in LanzaJet and SGLT (see Note 6 - Investments for further details). The table below summarizes amounts related to transactions with these related parties (in thousands): As of March 31, 2024 December 31, 2023 Accounts receivable $ 2,377 $ 2,190 Contract Assets 606 $ 659 Notes receivable 5,522 5,436 Accounts payable 221 582 The following table presents revenue from related parties per disaggregated revenue categories: Three Months Ended March 31, 2024 2023 Revenue from related parties, included within Licensing $ 580 $ 553 Revenue from related parties, included within Engineering and other services 328 420 The main transactions with related parties are described below: LanzaJet The Company and LanzaJet have entered into a master service agreements defining the terms when LanzaJet is a subcontractor for some of the Company’s projects, and conversely, when the Company is a subcontractor for LanzaJet’s projects. The accounts payable balance is for work that LanzaJet performed as a subcontractor to the Company. In connection with the formation of LanzaJet, the Company entered into a transition services agreement with LanzaJet, refer to Note 6 - Investments , for more information. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the three months ended March 31, 2024 and 2023, the Company recognized revenue from related parties of approximately $31 and $45, respectively, under the transition services agreement. The Company also provides certain engineering and other services related to a gas-to-jet demonstration plant currently in development by LanzaJet pursuant to the Investment Agreement described in Note 6 - Investments and other projects whereby LanzaJet is the customer. The Company recognized revenue of $12 for the three months ended March 31, 2024 and $338 for the three months ended March 31, 2023. In December 2023, LanzaTech additionally sold LanzaJet the right to utilize some of LanzaTech’s completed engineering work as a basis for future LanzaJet projects, and recognized $58 in deferred profit for the three months ended March 31, 2024. LanzaJet Note Purchase Agreement On November 9, 2022, the Company and the other LanzaJet shareholders entered into a Note Purchase Agreement (the “Note Purchase Agreement”), pursuant to which LanzaJet Freedom Pines Fuels LLC (“FPF”), a wholly owned subsidiary of LanzaJet, will issue, from time to time, notes in an aggregate principal amount of up to $147.0 million (the “Notes”), comprised of approximately $113.5 million aggregate principal amount of 6.00% Senior Secured Notes maturing December 31, 2043 and $33.5 million aggregate principal amount of 6.00% Subordinated Secured Notes maturing December 31, 2043. The Company committed to purchase $5.5 million of Subordinated Secured Notes, which was funded on May 1, 2023. The Senior Secured Notes are secured by a security interest over substantially all assets of FPF, and both the Senior Secured Notes and the Subordinated Secured Notes are secured by a security interest over the intellectual property owned or in-licensed by LanzaJet. Each purchaser of Notes under the Note Purchase Agreement also received a warrant for the right to purchase 575,000 shares of common stock of LanzaJet for each $10 million of Notes purchased by such purchaser for an exercise price of $0.01 per share. The warrants are exercisable when the related loan commitment is funded, and may be exercised until the earlier of the third anniversary following the date the holder’s loan commitment is fully funded, or the end of the availability period as defined in the Note Purchase Agreement if the commitment has not been fully funded. In the case of the Company, LanzaTech received warrants to purchase 316,250 shares of common stock of LanzaJet, which became exercisable by the Company when the note was funded on May 1, 2023. The Company exercised the warrants in January 2024. Upon funding of the Notes, the warrants meet the accounting criteria to be considered in-substance common stock, and are accounted for as part of the equity-method investment. Refer to Note 6 - Investments. The Note Purchase Agreement may be amended with the approval of holders of at least 66 2∕3% of the Notes, except with respect to certain rights that require approval of all holders to amend. Upon an event of default under the Note Purchase Agreement, each purchaser may accelerate the payment of its own Notes. Enforcement against the collateral securing the Notes requires the approval of certain holders as specified in the Notes. SGLT The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, small-size equipment and consulting services. For the three months ended March 31, 2024 and 2023, the Company recognized revenue of approximately $51 and $0, respectively. The Company also provided engineering services and incurred costs of $185 and $249 for the three months ended March 31, 2024 and 2023, respectively. Additionally, LanzaTech and SGLT entered into a license agreement in 2019, subsequently amended in August 2023, to provide SGLT with the right to sublicense the intellectual property that LanzaTech previously licensed to SGLT. In exchange, the Company is entitled to receive fixed licensing consideration, calculated as a percentage of the maximum amount of royalties owed to SGLT from its sublicenses. Prior to June 2023, the Company was only entitled to royalties from SGLT, if SGLT received sublicense royalty payments. For the three months ended March 31, 2024 and 2023, the Company did not recognize any sublicensing revenue.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation The Company may be involved in legal proceedings and exposed to potential claims in the normal course of business. As of March 31, 2024 and December 31, 2023, the Company does not have any reasonably possible or probable losses from such claims. Commitments In November 2022, the Company entered into a lease for real estate to expand its headquarters in Skokie, Illinois. The lease was subsequently amended in December 2023. The lease contains multiple lease components, and the commencement date for some lease components will occur in April, May, and October 2024. Accordingly, for

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On May 9, 2024, the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) and a Terms Agreement (the “Terms Agreement” and, together with the Sales Agreement, the “ATM Agreements”) with B. Riley Securities, Inc. (“B. Riley Securities”), pursuant to which the Company may, from time to time, offer and sell through or to B. Riley Securities, as sales agent or principal, shares of the Company’s common stock, having an aggregate offering price of up to $100 million . The ATM Agreements are effective upon the filing of a registration statement on Form S-3, including a base prospectus, relating to certain securities including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934 (the “Registration Statement”). Sales of the Shares under the ATM Agreements, if any, may be made by any method that is deemed an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The Shares will be offered through or to B. Riley Securities, acting as agent in connection with agency transactions or as principal in connection with any principal transactions. Pursuant to the Terms Agreement, the Company will have the right, but not the obligation, from time to time at its sole discretion, for as long as the Sales Agreement remains effective, to direct B. Riley Securities on any trading day to act on a principal basis and purchase up to $180,000 per day, up to $900,000 per week, and up to $40 million per twelve-month period, subject to any applicable limitations pursuant to the rules and regulations of The Nasdaq Stock Market, LLC (the aggregate amount so purchased by B. Riley Securities under the Terms Agreement, the “Commitment”), which Commitment will be included within the aggregate offering price of up to $100 million of Common Stock sold pursuant to the ATM Agreements; provided, however, that only one principal sale may be requested per day unless otherwise agreed to by B. Riley Securities. B. Riley Securities will be entitled to receive from the Company a commission in an amount (i) up to 3.0% of the gross sales price per Share sold through it as agent in agency transactions and (ii) equal to 5.0% of the purchase price per Share sold to B. Riley Securities, as principal in principal transactions. The Company has agreed to provide B. Riley Securities with customary indemnification and contribution rights. The Company will also reimburse B. Riley Securities for certain specified expenses as set forth in the Sales Agreement. The Sales Agreement may be terminated by either B. Riley Securities or the Company, as permitted therein. The Sales Agreement will automatically terminate upon the sale of all of the Shares subject to the Sales Agreement.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net income (loss)	$ (25,508)	$ (63,312)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. The condensed consolidated financial statements include the accounts of LanzaTech Global, Inc. and its wholly-owned consolidated subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in LanzaTech's Annual Report on Form 10-K for the year ended December 31, 2023. The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances: • Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company; • Legacy LanzaTech’s existing senior management team comprise senior management of the Company; • The operations of the Company primarily represent operations of Legacy LanzaTech; and • In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets. For more information on the Business Combination, see Note 3 - Reverse Recapitalization .
Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. The condensed consolidated financial statements include the accounts of LanzaTech Global, Inc. and its wholly-owned consolidated subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in LanzaTech's Annual Report on Form 10-K for the year ended December 31, 2023. The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances: • Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company; • Legacy LanzaTech’s existing senior management team comprise senior management of the Company; • The operations of the Company primarily represent operations of Legacy LanzaTech; and • In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets. For more information on the Business Combination, see Note 3 - Reverse Recapitalization .
Going Concern	Going Concern
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of equity awards granted to both employees and non-employees, valuation of common stock prior to the close of the Business Combination, revenue recognized over time, AM SAFE and Brookfield SAFE obligations, AM SAFE warrants, the Forward Purchase Agreement and the Private Placement Warrants. The Company uses the percentage of completion for the input method to recognize revenue over time for certain contracts with customers. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance. Most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to the Revenue Recognition section in Note 2 - Summary of Significant Accounting Policies hereunder. Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.
Cash and Cash Equivalents, Restricted Cash	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of March 31, 2024 and December 31, 2023, the Company had $56,747 and $75,585 of cash and cash equivalents, respectively. Restricted Cash
Forward Purchase Agreement	Forward Purchase Agreement On February 3, 2023, the Company entered into a Forward Purchase Agreement (“FPA”) with ACM. On the same date, ACM partially assigned its rights under the FPA to Vellar. ACM and Vellar are together referred to as the “Purchasers”. Pursuant to the Forward Purchase Agreement, the Purchasers obtained 5,916,514 common shares (“Recycled Shares”) on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60,096 was funded by the use of AMCI trust account proceeds as a partial prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption 3 years from the date of the Business Combination (“Maturity Date”). The Maturity Date may be accelerated, at the Purchasers discretion, if the Company share price trades below $3.00 per share for any 50 trading days during a 60 day consecutive trading-day period or the Company is delisted. On any date following the Business Combination, the Purchasers also have the option to early terminate the arrangement in whole or in part by providing optional early termination notice to the Company (the “Optional Early Termination”). For those shares early terminated (the “Terminated Shares”), the Purchasers will owe the Company an amount equal to the Terminated Shares times the Redemption Price, which may be reduced in the case of certain dilutive events (“Reset Price”). At the Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”). In addition to the Maturity Consideration, on the Maturity Date, the Company shall pay to the Purchasers an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5,079 (the “Share Consideration”). If the Purchasers were to utilize their Optional Early Termination to terminate the FPA early in its entirety, neither the Maturity Consideration nor the Share Consideration would be due to the Purchasers. The Purchasers’ Optional Early Termination economically results in the prepaid forward contract being akin to a written put option with the Purchaser’s right to sell all or a portion of the 5,916,514 common shares to the Company. The Company is entitled over the 36-month maturity period to either a return of the prepayment or the underlying shares, which the Purchasers will determine at their sole discretion. The FPA consists of three freestanding financial instruments which are accounted for as follows: 1) The total prepayment of $60,547 (“Prepayment Amount”), which is accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares and sale of shares to the Purchasers pursuant to a subscription agreement. 2) The “FPA Put Option” which includes both the in-substance written put option and the portion of the Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”). The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The initial fair value of the FPA Put Option and subsequent changes in fair value of the FPA Put Option are recorded within Other income (expense), net on the condensed consolidated statements of operations and comprehensive loss.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from exchange transactions in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to biorefining (formerly known as carbon capture and transformation) which includes feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are: (1) joint development and contract research activities to develop and optimize novel biocatalysts, related processes and technologies, and (2) supply of chemical building blocks for sustainable products produced using the Company’s proprietary technologies (referred to as CarbonSmart). Revenue is measured based on the consideration specified in a contract with a customer. The Company records taxes collected from customers and remitted to governmental authorities on a net basis. The Company’s payment terms are between 30-60 days and can vary by customer type and products offered. Management has evaluated the terms of the Company’s arrangements and determined that they do not contain significant financing components. Biorefining The Company provides feasibility studies and basic design and engineering services used for detailed design, procurement, and construction of commercial plants that utilize the Company’s technologies, along with the sale of microbes and media. The services provided are recognized as a performance obligation satisfied over time. Revenue is recognized using the cost-to-cost input method for certain engineering services, or the percentage of completion method as performance obligations are satisfied. Revenue for the sale of microbes and media is at a point in time, depending on when control transfers to the customer. The Company licenses intellectual property to generate recurring revenue, in the case of running royalties, or one-time revenue, in the case of fixed consideration royalties, when its customers deploy the Company’s technology in their biorefining plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later. Grants received to perform engineering services, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue as the qualifying costs related to the grant have been incurred. Joint Development and Contract Research The Company performs R&D services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. The Company engages in two main types of R&D services – joint development agreements, and contract research, including projects with the U.S. Department of Energy and other US or foreign government agencies. Such services are recognized as a performance obligation satisfied over time. Revenue is recognized based on milestone completion, when payments are contingent upon the achievement of such milestones, or based on percentage-completion method when enforceable rights to payment exist. When no milestones or phases are clearly defined, management has determined that the cost incurred, input method, is an appropriate measure of progress towards complete satisfaction of the performance obligations under ASC 606 , and estimates its variable consideration under the expected value method. Revenue is not recognized in advance of customer acceptance of a milestone when such acceptance is contractually required. Payments for R&D services with no contractual payments are not due from customers until a technical report is submitted; therefore, a contract asset is recognized at milestone completion but prior to the submission of a technical report. The contract asset represents the Company’s right to consideration for the services performed at milestone completion. Occasionally, customers provide payments in advance of the Company providing services which creates a contract liability for the Company. The contract liability represents the Company's obligation to provide services to a customer. CarbonSmart The Company purchases ethanol from the customers who have deployed our proprietary technologies in their biorefining plants and sells it and its derivatives as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from sales of CarbonSmart products in the condensed consolidated statements of operations and comprehensive loss. Collaboration Arrangements The Company has certain partnership agreements that are within the scope of ASC 808, Collaborative Arrangements , which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transaction under the collaborative arrangements is determined based on the nature of the contractual terms of the arrangement, along with the nature of the operations of the participants. The Company’s collaborative agreements generally include a provision of R&D services related to novel technologies and biocatalysts. Amounts received for these services are classified as Revenue from collaborative arrangements in the consolidated statements of operations and comprehensive loss. The Company's R&D services are a major part of the Company's ongoing operations and therefore ASC 606 is applied to recognize revenue.
Cost of Revenues	Cost of Revenues The Company’s R&D, engineering, and other direct costs of services and goods related to revenue agreements with customers, related parties, and collaborative partners represent cost of revenue. Costs include both internal and third-party fixed and variable costs and include materials, supplies, labor, and fringe benefits.
Research and Development	Research and Development We incur costs associated with various R&D activities and expense them as incurred.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access; Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities; and Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement , approximates the carrying amounts represented in the accompanying consolidated balance sheets, primarily due to their short-term nature, except for the warrant liability.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Revenue generated from the Company’s customers and grant providers from outside of the United States for the three months ended March 31, 2024 and 2023 was approximately 56% and 62%, respectively.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of cash and cash equivalents	The following represents a reconciliation of Cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of March 31, 2024 and December 31, 2023. As of March 31, 2024 December 31, 2023 Cash and cash equivalents $ 56,747 $ 75,585 Restricted cash (presented within Other current assets) 702 699 Cash, cash equivalents and restricted cash $ 57,449 $ 76,284
Customer concentration risk	Our largest contracting entities represent 10% or greater of revenue and were as follows for the three months ended March 31, 2024 and 2023: Three Months Ended March 31, 2024 2023 Customer A 18 % — % Customer B 11 % 30 % Customer C 11 % 4 % Customer D 10 % 1 % Customer E 8 % 10 % Customer F 7 % 13 %

Reverse Recapitalization (Table

Reverse Recapitalization (Tables)	3 Months Ended
Reverse Recapitalization (Tables)	Mar. 31, 2024
Reverse Recapitalization [Abstract]
Schedule of reverse recapitalization	The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were: Shares Percentage Legacy LanzaTech shares 167,324,363 85.3 % Public stockholders 10,398,374 5.3 % PIPE shares 18,500,000 9.4 % Total 196,222,737 100 % The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statements of cash flows for the period ended March 31, 2023: Recapitalization Cash - AMCI trust account 1 $ 64,090 Cash - PIPE financing 155,000 Less: Transaction costs allocated to equity (5,709) Effect of the Business Combination and PIPE financing $ 213,381 __________________ (1) The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses. The following table reconciles the elements of the Business Combination and PIPE financing to the change in Additional paid-in capital on the condensed consolidated statement of changes in redeemable preferred stock and shareholders' equity/deficit: Recapitalization Cash - AMCI trust account $ 64,090 Public Warrants and Private Placement Warrants recorded on the Closing Date (4,624) Cash - PIPE financing 155,000 Conversion of the AM SAFE 29,730 Transaction costs allocated to equity (7,223) $ 236,973 Less: par value of shares held by PIPE investors and public stockholders (3) Total additional paid-in capital from recapitalization $ 236,970

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted net loss per share	The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts): Three Months Ended March 31, 2024 2023 Numerator: Net loss for basic and diluted earnings per common share $ (25,508) $ (63,312) Unpaid cumulative dividends on preferred stock — (4,117) Net loss allocated to common shareholders $ (25,508) $ (67,429) Denominator: Weighted-average shares used in calculating net loss per share, basic and diluted 196,974,508 116,530,963 Net loss per common share, basic and diluted (1) $ (0.13) $ (0.58) __________________ (1) In periods in which the Company reports a net loss, all common stock equivalents are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on loss per share.
Schedule of antidilutive securities excluded from computation	As of March 31, 2024 and 2023, common stock equivalents not included in the computation of loss per share because their effect would be antidilutive include the following: March 31, 2024 2023 Options 16,167,460 14,355,066 RSUs 5,944,771 — Brookfield SAFE 5,000,000 5,000,000 Warrants 16,657,686 16,657,686 Total 43,769,917 36,012,752

Revenues (Tables)

Revenues (Tables)	3 Months Ended
Revenues (Tables)	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Disaggregated revenue	The following table presents disaggregated revenue in the following categories (in thousands): Three Months Ended March 31, 2024 2023 Contract Types: Licensing $ 580 $ 553 Engineering and other services 4,456 5,801 Biorefining revenue $ 5,036 $ 6,354 Joint development agreements 2,872 2,036 Contract research 1,473 1,256 Joint development and contract research revenue $ 4,345 $ 3,292 CarbonSmart product 863 — Total Revenue $ 10,244 $ 9,646 The following table presents revenue from partners in collaborative arrangements and from grant contributions which are included in the table above as follows (in thousands): Three Months Ended March 31, 2024 2023 Revenue from partners in collaborative agreements included in the Joint development agreements above 2,223 $ 1,088 Revenue from grant contributions included in Engineering and other services above 1,156 3,067 The following table presents disaggregation of the Company’s revenues by customer location for the three months ended March 31, 2024 and 2023 (in thousands): Three Months Ended March 31, 2024 2023 North America $ 4,458 $ 4,232 Europe, Middle East, Africa (EMEA) 4,580 4,711 Asia 1,206 50 Australia — 653 Total Revenue $ 10,244 $ 9,646
Changes in contract assets and liabilities	The following table provides changes in contract assets and liabilities (in thousands): Current Contract Assets Current Contract Liabilities Non-current Contract Liabilities Balance as of December 31, 2023 $ 28,238 $ 3,198 $ 8,233 Additions to unbilled accounts receivable 10,120 — — Increases due to cash received — 3,208 — Unbilled accounts receivable recognized in trade receivables (9,091) — — Decrease on revaluation on currency (108) (1) (123) Reclassification from long-term to short-term — 672 (672) Reclassification to revenue as a result of performance obligations satisfied — (3,263) — Balance as of March 31, 2024 $ 29,159 $ 3,814 $ 7,438
Remaining performance obligations	Remaining performance obligations consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Current $ 3,814 $ 3,198 Non-current 7,438 8,233 Total $ 11,252 $ 11,431

Investments (Tables)

Investments (Tables)	3 Months Ended
Investments (Tables)	Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Debt securities, held-to-maturity	HTM debt securities are classified as short-term or long-term based upon the contractual maturity of the underlying investment. March 31, 2024 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Accrued Interest Short-term US Treasury bills and notes 10,661 0 $ (1) $ 10,660 $ 45 Corporate debt securities 21,158 4 (25) 21,137 311 Yankee debt securities 3,000 — — 3,000 87 Total debt securities due within a year $ 34,819 $ 4 $ (26) $ 34,797 $ 443 Total HTM Debt Securities 34,819 4 (26) 34,797 443 December 31, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Accrued Interest Short-term US Treasury bills and notes 20,423 6 $ — $ 20,429 $ 14 Corporate debt securities 21,736 14 (33) 21,717 209 Yankee debt securities 3,000 — (8) 2,992 43 Total debt securities due within a year $ 45,159 $ 20 $ (41) $ 45,138 $ 266 Total HTM Debt Securities 45,159 20 (41) 45,138 266
Investments	The Company’s equity investments consisted of the following (in thousands): As of March 31, 2024 December 31, 2023 Equity Method Investment in LanzaJet $ 6,354 $ 7,066 Equity Security Investment in SGLT 14,990 14,990 Total Investment $ 21,344 $ 22,056

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
Fair Value (Tables)	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of assets and liabilities that are measured at fair value on a recurring basis	The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of March 31, 2024 and December 31, 2023 (in thousands): Fair Value Measurement as of March 31, 2024 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 39,298 $ — $ — $ 39,298 Total assets $ 39,298 $ — $ — $ 39,298 Liabilities: FPA Put Option liability $ — $ — $ 50,192 $ 50,192 Fixed Maturity Consideration — — 7,604 7,604 Brookfield SAFE liability — — 15,475 15,475 Private placement warrants — — 2,148 2,148 Public warrants 1,864 — — 1,864 Total liabilities $ 1,864 $ — $ 75,419 $ 77,283 Fair Value Measurement as of December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 28,058 $ — $ — $ 28,058 Liabilities: FPA Put Option liability — — 37,523 37,523 Fixed Maturity Consideration — — 7,228 7,228 Brookfield SAFE liability — — 25,150 25,150 Private placement warrants — — 3,915 3,915 Public warrants 3,699 — — 3,699 Total Liabilities $ 3,699 $ — $ 73,816 $ 77,515
Summary of quantitative information regarding Level 3 fair value measurement inputs	The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of March 31, 2024 and December 31, 2023: March 31, 2024 December 31, 2023 Stock price $ 3.10 $ 5.03 Term (in years) 1.86 2.11 Expected volatility 50.0 % 50.0 % Risk-free interest rate 4.60 % 4.16 % Expected dividend yield — % — % Significant inputs for Level 3 Brookfield SAFE measurement at March 31, 2024 and December 31, 2023 are as follows: March 31, 2024 December 31, 2023 Initial purchase amount $ 50,000 $ 50,000 Liquidity price $ 10.00 $ 10.00 Stock price $ 3.10 $ 5.03 The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of March 31, 2024 and December 31, 2023: March 31, 2024 December 31, 2023 Stock price $ 3.10 $ 5.03 Exercise price $ 11.50 $ 11.50 Term (in years) 3.86 4.11 Expected volatility 57.5 % 45.0 % Risk-free interest rate 4.32 % 3.92 % Expected dividend yield — % — %
Summary of change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs	The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands): FPA Put Option Fixed Maturity Consideration Brookfield SAFE Private placement warrants Balance as of January 1, 2024 $ (37,523) $ (7,228) $ (25,150) $ (3,914) (Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss (12,669) (376) 9,675 1,766 Balance as of March 31, 2024 $ (50,192) $ (7,604) $ (15,475) $ (2,148) FPA Put Option Fixed Maturity Consideration Shortfall Warrants Warrants on Preferred Shares AM SAFE liability AM SAFE warrant Brookfield SAFE Private placement warrants Balance as of January 1, 2023 $ — $ — $ — $ (2,119) $ (28,986) $ (1,989) $ (50,000) $ — Recognized as a result of the Business Combination — — — — — — — (2,148) (Loss) gain recognized in other expense, net on the consolidated statement of operations and comprehensive loss (44,593) (6,967) (5,104) (3,770) (744) 189 30,600 (477) Conversion of warrants to preferred shares — — — 5,889 — — — — Conversion of SAFE liability to equity classification — — — — 29,730 — — — Reclassification of warrant to equity — — — — 1,800 — — Balance as of March 31, 2023 $ (44,593) $ (6,967) $ (5,104) $ — $ — $ — $ (19,400) $ (2,625)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
Share-Based Compensation (Tables)	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Restricted stock units activity	A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table: Time-based RSUs Market-based RSUs Shares (in thousands) Weighted Average Grant Date Fair Value Shares Weighted Average Grant Date Fair Value January 1, 2024 3,155 3.51 3,930 $ 1.69 Vested (1,033) 3.44 — — Cancelled/forfeited (107) 3.45 — — March 31, 2024 2,015 3.54 3,930 $ 1.69
Stock options activity	Stock option awards outstanding as of March 31, 2024 and changes during the period ended March 31, 2024 were as follows: Shares subject to option (thousands) Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (thousands) Outstanding at January 1, 2024 16,412 $ 1.96 Vested and expecting to vest at January 1, 2024 16,412 1.96 Exercisable at January 1, 2024 10,869 $ 1.49 Granted — — Exercised (162) 1.45 Cancelled/forfeited (83) 1.45 Outstanding at March 31, 2024 16,167 $ 1.97 5.92 $ 20,605 Vested and expecting to vest at March 31, 2024 16,167 1.97 5.92 20,605 Exercisable at March 31, 2024 12,351 $ 1.66 5.21 $ 18,539

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
Related Party Transactions (Tables)	Mar. 31, 2024
Related Party Transactions [Abstract]
Amounts related to transactions with related parties	The table below summarizes amounts related to transactions with these related parties (in thousands): As of March 31, 2024 December 31, 2023 Accounts receivable $ 2,377 $ 2,190 Contract Assets 606 $ 659 Notes receivable 5,522 5,436 Accounts payable 221 582 The following table presents revenue from related parties per disaggregated revenue categories: Three Months Ended March 31, 2024 2023 Revenue from related parties, included within Licensing $ 580 $ 553 Revenue from related parties, included within Engineering and other services 328 420 The main transactions with related parties are described below:

Description of the Business (De

Description of the Business (Details) - plant	Mar. 31, 2024	Mar. 31, 2023
China
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Commercial plants operated	4	3
India
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Commercial plants operated	1
Belgium
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Commercial plants operated	1

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Basis of Presentation and Going Concern (Details) - USD ($) $ in Thousands		3 Months Ended
	Feb. 08, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accounting Policies [Abstract]
Voting rights stock held	85.30%
Cash and cash equivalents		$ 56,747		$ 75,585
Held-to-maturity securities		34,819		45,159
Accumulated deficit		(857,380)		$ (831,872)
Net cash used in operating activities		(28,289)	$ (33,810)
Net income (loss)		$ (25,508)	$ (63,312)
Proceeds from divestiture of businesses, net	$ 153,285

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Cash and cash equivalents	$ 56,747	$ 75,585

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash Reconciliation (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 56,747	$ 75,585
Restricted cash (presented within Other current assets)	702	699
Cash, cash equivalents and restricted cash	$ 57,449	$ 76,284	$ 145,786	$ 83,710

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Forward Purchase Agreement (Details) $ / shares in Units, $ in Thousands	Feb. 08, 2023 shares	Feb. 03, 2023 USD ($) consecutiveTradingDay financial_instrument tradingDay $ / shares shares
Derivative [Line Items]
Shares issued in transaction (in shares)	196,222,737
Trigger share price (usd per share) \| $ / shares		$ 3
Trading days \| tradingDay		50
Consecutive trading days \| consecutiveTradingDay		60
Forward Contracts
Derivative [Line Items]
Shares issued in transaction (in shares)		5,916,514
Sale of stock price (usd per share) \| $ / shares		$ 10.16
Purchase price \| $		$ 60,096
Derivative term		3 years
Number of freestanding financial instruments \| financial_instrument		3
Forward purchase agreement prepayment \| $		$ 60,547
Forward Contracts \| Maturity Consideration
Derivative [Line Items]
Shares to issue (in shares)		7,500,000
Maturity consideration (usd per share) \| $ / shares		$ 2
Maturity consideration (in shares)		500,000
Maturity consideration, amount \| $		$ 5,079
Forward Contracts \| Fixed Maturity Consideration
Derivative [Line Items]
Shares issued in transaction (in shares)		5,916,513
Shares to issue (in shares)		7,500,000
Maturity consideration (usd per share) \| $ / shares		$ 2
Maturity consideration, amount \| $		$ 3,167

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Concentration of Credit Risk and Other Risks and Uncertainties (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue Benchmark \| Geographic Concentration Risk \| Non-US
Concentration Risk [Line Items]
Concentration risk, percentage	56%	62%
Revenue Benchmark \| Customer Concentration Risk \| Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	18%	0%
Revenue Benchmark \| Customer Concentration Risk \| Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	11%	30%
Revenue Benchmark \| Customer Concentration Risk \| Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	11%	4%
Revenue Benchmark \| Customer Concentration Risk \| Customer D
Concentration Risk [Line Items]
Concentration risk, percentage	10%	1%
Revenue Benchmark \| Customer Concentration Risk \| Customer E
Concentration Risk [Line Items]
Concentration risk, percentage	8%	10%
Revenue Benchmark \| Customer Concentration Risk \| Customer F
Concentration Risk [Line Items]
Concentration risk, percentage	7%	13%
Accounts Receivable \| Geographic Concentration Risk \| Non-US
Concentration Risk [Line Items]
Concentration risk, percentage	45%		49%

Reverse Recapitalization - Narr

Reverse Recapitalization - Narrative (Details) $ / shares in Units, $ in Thousands	Feb. 08, 2023 USD ($) $ / shares shares	Mar. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares
Schedule Of Reverse Recapitalization [Line Items]
Common shares, shares authorized (in shares)	196,222,737	400,000,000	400,000,000
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Warrants outstanding (in shares)	12,574,200
Recapitalization exchange ratio	4.3747
Shares issued in transaction (in shares)	196,222,737
Recapitalization costs \| $	$ 7,223
Priced At $10.00 Per Share
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	15,500,000
Stock repurchased (in dollars per share) \| $ / shares	$ 10
Public stockholders
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	10,398,374
AMCI
Schedule Of Reverse Recapitalization [Line Items]
Stock repurchased (in shares)	8,351,626
Stock repurchased (in dollars per share) \| $ / shares	$ 10.16
PIPE shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	18,500,000
AM SAFE Liability
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	3,000,000

Reverse Recapitalization - Sche

Reverse Recapitalization - Schedule of Shares (Details)	Feb. 08, 2023 shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	196,222,737
Percentage	100%
Legacy LanzaTech shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	167,324,363
Percentage	85.30%
Public stockholders
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	10,398,374
Percentage	5.30%
PIPE shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	18,500,000
Percentage	9.40%

Reverse Recapitalization - Cash

Reverse Recapitalization - Cash Flow Reconciliation (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Reverse Recapitalization [Abstract]
Cash - AMCI trust account	$ 64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
Proceeds From Reverse Recapitalization Transaction	236,973
Less: Transaction costs allocated to equity	(5,709)
Less: par value of shares held by PIPE investors and public stockholders	(3)
Effect of the Business Combination and PIPE financing	213,381
Total additional paid-in capital from recapitalization	$ 236,970

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Calculation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net loss for basic and diluted earnings per common share	$ (25,508)	$ (63,312)
Unpaid cumulative dividends on preferred stock	0	(4,117)
Net loss allocated to common shareholders	$ (25,508)	$ (67,429)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average shares used in calculating net loss per share, basic (in shares)	196,974,508	116,530,963
Weighted-average shares used in calculating net loss per share, diluted (in shares)	196,974,508	116,530,963
Net loss per common share, basic (in dollars per share)	$ (0.13)	$ (0.58)
Net loss per common share, diluted (in dollars per share)	$ (0.13)	$ (0.58)

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Shares (Details) - shares	3 Months Ended
Net Loss Per Share - Antidilutive Shares (Details) - shares	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	43,769,917	36,012,752
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	16,167,460	14,355,066
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	5,944,771	0
Brookfield SAFE
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	5,000,000	5,000,000
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	16,657,686	16,657,686

Revenues - Disaggregated Revenu

Revenues - Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 10,244	$ 9,646
Collaborative Arrangement
Disaggregation of Revenue [Line Items]
Total revenue	2,223	1,088
Biorefining revenue
Disaggregation of Revenue [Line Items]
Total revenue	5,036	6,354
Licensing
Disaggregation of Revenue [Line Items]
Total revenue	580	553
Engineering and other services
Disaggregation of Revenue [Line Items]
Total revenue	4,456	5,801
Grant contributions - Engineering and other services
Disaggregation of Revenue [Line Items]
Total revenue	1,156	3,067
Joint development and contract research revenue
Disaggregation of Revenue [Line Items]
Total revenue	4,345	3,292
Joint development agreements
Disaggregation of Revenue [Line Items]
Total revenue	2,872	2,036
Contract research
Disaggregation of Revenue [Line Items]
Total revenue	1,473	1,256
CarbonSmart product
Disaggregation of Revenue [Line Items]
Total revenue	$ 863	$ 0

Revenues - Disaggregation by Cu

Revenues - Disaggregation by Customer Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 10,244	$ 9,646
North America
Disaggregation of Revenue [Line Items]
Total revenue	4,458	4,232
Europe, Middle East, Africa (EMEA)
Disaggregation of Revenue [Line Items]
Total revenue	4,580	4,711
Asia
Disaggregation of Revenue [Line Items]
Total revenue	1,206	50
Australia
Disaggregation of Revenue [Line Items]
Total revenue	$ 0	$ 653

Revenues - Contract Balances (D

Revenues - Contract Balances (Details) $ in Thousands	3 Months Ended
Revenues - Contract Balances (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Current Contract Assets
Beginning balance	$ 28,238
Additions to unbilled accounts receivable	10,120
Unbilled accounts receivable recognized in trade receivables	(9,091)
Decrease on revaluation on currency	(108)
Ending balance	29,159
Current Contract Liabilities
Beginning balance	3,198
Increases due to cash received	3,208
Decrease on revaluation on currency	(1)
Reclassification from long-term to short-term	672
Reclassification to revenue as a result of performance obligations satisfied	(3,263)
Ending balance	3,814
Non-current Contract Liabilities
Beginning balance	8,233
Decrease on revaluation on currency	(123)
Reclassification from long-term to short-term	(672)
Ending balance	$ 7,438

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Billed accounts receivable, net of allowance	$ 10,689	$ 11,157

Revenues - Remaining Performanc

Revenues - Remaining Performance Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Current	$ 3,814	$ 3,198
Non-current	7,438	8,233
Total	$ 11,252	$ 11,431

Investments - Held to Maturity

Investments - Held to Maturity Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	$ 34,819	$ 45,159
Gross Unrealized Gains	4	20
Gross Unrealized Losses	(26)	(41)
Estimated Fair Value	34,797	45,138
Accrued Interest	443	266
US Treasury bills and notes
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	10,661	20,423
Gross Unrealized Gains	0	6
Gross Unrealized Losses	(1)	0
Estimated Fair Value	10,660	20,429
Accrued Interest	45	14
Corporate debt securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	21,158	21,736
Gross Unrealized Gains	4	14
Gross Unrealized Losses	(25)	(33)
Estimated Fair Value	21,137	21,717
Accrued Interest	311	209
Yankee debt securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	3,000	3,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	(8)
Estimated Fair Value	3,000	2,992
Accrued Interest	$ 87	$ 43

Investments - Narrative (Detail

Investments - Narrative (Details) $ / shares in Units, ¥ in Thousands				2 Months Ended	3 Months Ended		12 Months Ended
	May 13, 2020 USD ($)	Sep. 28, 2011 USD ($)	Sep. 28, 2011 CNY (¥)	Apr. 04, 2021 USD ($) investment_round shares	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022	Nov. 09, 2022 $ / shares
Schedule of Equity Method Investments [Line Items]
Allowance for credit losses related to held-to-maturity securities					$ 0		$ 0
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares									$ 0.01
Impairment on equity method investments					0		0
Dividends from equity investments					$ 0	$ 0
LanzaJet
Schedule of Equity Method Investments [Line Items]
Contribution of intellectual property	$ 15,000,000
Ownership percentage	37.50%			23%	22.89%
Revenue					$ 580,000	553,000
Deferred revenue					$ 4,704,000		5,375,000
Profit amortization period					15 years
Number of rounds of investments \| investment_round				2
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares									$ 0.01
Gain from equity method investment					$ 77,000
Ownership if diluted (in percent)					22.38%
Contingent right to receive additional interest (in shares) \| shares				45,000,000
Equity method investments cost				$ 0
Carrying value less than proportionate share of book value					$ 3,400,000		$ 3,400,000
LanzaJet \| Intra-entity
Schedule of Equity Method Investments [Line Items]
Revenue					$ 92,000	$ 118,000
SGLT
Schedule of Equity Method Investments [Line Items]
Ownership percentage		30%	30%					9.31%
SGLT \| Intellectual Property
Schedule of Equity Method Investments [Line Items]
Contribution of intellectual property		$ 4,000,000	¥ 25,800

Investments - Equity Method Inv

Investments - Equity Method Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment in LanzaJet	$ 6,354	$ 7,066
Equity Security Investment in SGLT	14,990	14,990
Total Investment	$ 21,344	$ 22,056

SAFE (Details)

SAFE (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Oct. 02, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Brookfield SAFE liability			$ 50,000,000
Required equity funding for qualifying projects			50,000,000
Required equity funding for qualifying projects, remaining amount reduction			$ 5,000,000
Stock price (in dollars per share)	$ 11.50		$ 10
Brookfield SAFE liability	$ 15,475,000	$ 25,150,000
Required equity funding			$ 500,000

Warrants (Details)

Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	May 13, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 27, 2023	Feb. 08, 2023	Nov. 09, 2022
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)						$ 0.01
Warrants outstanding (in shares)					12,574,200
Shortfall Warrants
Warrants
Price of warrant (in dollars per warrant)				$ 10
Fair value of shares	$ 3,063		$ 5,104
Gain on reclassification	$ 2,042
Shortfall Warrants \| ACM
Warrants
Warrants issued (in shares)				2,073,486
Shortfall Warrants \| Vellar Opportunity Fund SPV LLC - Series 10
Warrants
Warrants issued (in shares)				2,010,000
Public Warrants and Private Placement Warrants
Warrants
Number of securities called by each warrant (in shares)		1
Price of warrant (in dollars per warrant)		$ 11.50
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 11.50
Threshold period days after the completion of the initial Business Combination for exercise of warrants		30 days
Public Warrants and Private Placement Warrants \| Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00
Warrants
Redemption price per public warrant (in dollars per share)		$ 0.01
Redemption period		30 days
Trigger price (in dollars per share)		$ 18
Threshold trading days for redemption of public warrants		20 days
Minimum threshold written notice period for redemption of public warrants		30 days
Public Warrants and Private Placement Warrants \| Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00
Warrants
Redemption price per public warrant (in dollars per share)		$ 0.10
Redemption period		30 days
Trigger price (in dollars per share)		$ 10
Public warrants
Warrants
Warrants outstanding (in shares)		7,499,924			7,499,924
Private placement warrants
Warrants
Warrants outstanding (in shares)		4,774,276			4,774,276

Forward Purchase Agreement - Na

Forward Purchase Agreement - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
	Feb. 03, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Derivative [Line Items]
Forward Purchase Agreement prepayment			$ (60,547)
FPA Put Option liability		$ 50,192		$ 37,523
Fixed Maturity Consideration		7,604		$ 7,228
Forward Contracts
Derivative [Line Items]
Derivative transaction costs		$ 451
Additional Paid-in Capital
Derivative [Line Items]
Forward Purchase Agreement prepayment	$ 60,547		$ (60,547)

Fair Value - Financial Assets a

Fair Value - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Oct. 02, 2022
Liabilities:
Brookfield SAFE liability			$ 50,000
Warrants	$ 4,012	$ 7,614
Fair Value, Recurring
Assets:
Cash equivalents	39,298	28,058
Total assets	39,298
Liabilities:
FPA Put Option liability	50,192	37,523
Fixed Maturity Consideration	7,604	7,228
Brookfield SAFE liability	15,475	25,150
Total liabilities	77,283	77,515
Fair Value, Recurring \| Private placement warrants
Liabilities:
Warrants	2,148	3,915
Fair Value, Recurring \| Public warrants
Liabilities:
Warrants	1,864	3,699
Fair Value, Recurring \| Level 1
Assets:
Cash equivalents	39,298	28,058
Total assets	39,298
Liabilities:
FPA Put Option liability	0	0
Fixed Maturity Consideration	0	0
Brookfield SAFE liability	0	0
Total liabilities	1,864	3,699
Fair Value, Recurring \| Level 1 \| Private placement warrants
Liabilities:
Warrants	0	0
Fair Value, Recurring \| Level 1 \| Public warrants
Liabilities:
Warrants	1,864	3,699
Fair Value, Recurring \| Level 2
Assets:
Cash equivalents	0	0
Total assets	0
Liabilities:
FPA Put Option liability	0	0
Fixed Maturity Consideration	0	0
Brookfield SAFE liability	0	0
Total liabilities	0	0
Fair Value, Recurring \| Level 2 \| Private placement warrants
Liabilities:
Warrants	0	0
Fair Value, Recurring \| Level 2 \| Public warrants
Liabilities:
Warrants	0	0
Fair Value, Recurring \| Level 3
Assets:
Cash equivalents	0	0
Total assets	0
Liabilities:
FPA Put Option liability	50,192	37,523
Fixed Maturity Consideration	7,604	7,228
Brookfield SAFE liability	15,475	25,150
Total liabilities	75,419	73,816
Fair Value, Recurring \| Level 3 \| Private placement warrants
Liabilities:
Warrants	2,148	3,915
Fair Value, Recurring \| Level 3 \| Public warrants
Liabilities:
Warrants	$ 0	$ 0

Fair Value - Level 3 Fair Value

Fair Value - Level 3 Fair Value Measurements (Details) $ in Thousands	Mar. 31, 2024 $ / shares USD ($)	Dec. 31, 2023 $ / shares USD ($)
Share price (usd per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	3.10	5.03
Brookfield SAFE, measurement input	3.10	5.03
Share price (usd per share) \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	3.10	5.03
Term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	1.86	2.11
Term (in years) \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	3.86	4.11
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	0.500	0.500
Expected volatility \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.575	0.450
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	0.0460	0.0416
Risk-free interest rate \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0432	0.0392
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	0	0
Expected dividend yield \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0
Exercise price (usd per share) \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	11.50	11.50
Initial purchase amount
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Brookfield SAFE, measurement input \| $	50,000	50,000
Liquidity price (usd per share)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Brookfield SAFE, measurement input	10	10

Fair Value - Narrative (Details

Fair Value - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
Fair Value - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Brookfield SAFE liability	$ 15,475		$ 25,150
Warrants
Change in fair value of derivative warrant liabilities	(13,277)	$ (20,979)
Other Expense \| Public warrants
Warrants
Change in fair value of derivative warrant liabilities	1,835	286
Other Expense \| Private placement warrants
Warrants
Change in fair value of derivative warrant liabilities	$ 1,766	$ 477

Fair Value - Change in Fair Val

Fair Value - Change in Fair Value of Derivative Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
FPA Put Option
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ (37,523)	$ 0
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(12,669)	(44,593)
Ending balance	(50,192)	(44,593)
Fixed Maturity Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(7,228)	0
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(376)	(6,967)
Ending balance	(7,604)	(6,967)
Shortfall Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		0
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss		(5,104)
Ending balance		(5,104)
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		(2,119)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss		(3,770)
Conversion of warrants to preferred shares		5,889
Ending balance		0
AM SAFE liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		(28,986)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss		(744)
Conversion of SAFE liability to equity classification		29,730
Ending balance		0
AM SAFE warrant
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		(1,989)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss		189
Reclassification of warrant to equity		1,800
Ending balance		0
Brookfield SAFE
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(25,150)	(50,000)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	9,675	30,600
Ending balance	(15,475)	(19,400)
Private placement warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(3,914)	0
Recognized as a result of the Business Combination		(2,148)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	1,766	(477)
Ending balance	$ (2,148)	$ (2,625)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended
Income Taxes - Narrative (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Foreign earnings repatriated	$ 0	$ 0
Deferred income taxes recognized	0	0
Income tax expense	$ 0	$ 0
Effective tax rate	0%	0%
Statutory tax rate	21%	21%

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) day installment share_type $ / shares shares	Mar. 31, 2023 USD ($)	Oct. 02, 2022 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (in dollars per share) \| $ / shares	$ 11.50		$ 10
Share price threshold trading days	20 days
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of share based stock schemes \| share_type	2
Vesting installments \| installment	3
Time-based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	$ 791
Unrecognized compensation costs	$ 6,760
Unrecognized cost, recognition period	1 year 11 months 15 days
Time-based RSUs \| Employees and Other Service Providers
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Time-based RSUs \| Director
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Market-based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Vesting component triggering event \| day	151
Compensation expense	$ 727
Unrecognized compensation costs	$ 2,471
Unrecognized cost, recognition period	1 year 5 months 19 days
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	$ 1,107	$ 764
Unrecognized compensation costs	$ 7,205
Unrecognized cost, recognition period	1 year 10 months 6 days
RSAs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	$ 2,741
Unrecognized cost, recognition period	10 years
Award requisite service period	3 years
Shares withheld for tax withholding obligation (in shares) \| shares	771,141
Tax payment	$ 7,650
Phantom RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting installments \| installment	3
Stock Appreciation Rights (SARs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting installments \| installment	3
Expiration period	10 years
Minimum \| Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period	2 years
Maximum \| Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period	5 years

Share-Based Compensation - Rest

Share-Based Compensation - Restricted Stock Units Activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Time-based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares) \| shares	3,155
Vested (in shares) \| shares	(1,033)
Cancelled/forfeited (in shares) \| shares	(107)
Ending balance (in shares) \| shares	2,015
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, weighted average fair value (usd per share) \| $ / shares	$ 3.51
Vested, weighted average fair value (usd per share) \| $ / shares	3.44
Cancelled/forfeited, weighted average fair value (usd per share) \| $ / shares	3.45
Ending balance, weighted average fair value (usd per share) \| $ / shares	$ 3.54
Market-based RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares) \| shares	3,930
Vested (in shares) \| shares	0
Cancelled/forfeited (in shares) \| shares	0
Ending balance (in shares) \| shares	3,930
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, weighted average fair value (usd per share) \| $ / shares	$ 1.69
Vested, weighted average fair value (usd per share) \| $ / shares	0
Cancelled/forfeited, weighted average fair value (usd per share) \| $ / shares	0
Ending balance, weighted average fair value (usd per share) \| $ / shares	$ 1.69

Share-Based Compensation - Stoc

Share-Based Compensation - Stock Option Award Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares)	16,412
Granted (in shares)	0
Exercised (in shares)	(162)
Cancelled/forfeited (in shares)	(83)
Ending balance (in shares)	16,167
Vested and expected to vest (in shares)	16,167	16,412
Exercisable (in shares)	12,351	10,869
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (usd per share)	$ 1.96
Granted (usd per share)	0
Exercised (usd per share)	1.45
Cancelled/forfeited (usd per share)	1.45
Ending balance (usd per share)	1.97
Vested and expecting to vest (usd per share)	1.97	$ 1.96
Exercisable (usd per share)	$ 1.66	$ 1.49
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, Weighted average remaining contractual term	5 years 11 months 1 day
Vested and expecting, Weighted average remaining contractual term	5 years 11 months 1 day
Exercisable, Weighted average remaining contractual term	5 years 2 months 15 days
Outstanding, Aggregate intrinsic value	$ 20,605
Vested and expecting to vest, Aggregate intrinsic value	20,605
Exercisable, Aggregate intrinsic value	$ 18,539

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Contract Assets	$ 29,159		$ 28,238
Total revenue	10,244	$ 9,646
Licensing
Related Party Transaction [Line Items]
Total revenue	580	553
Engineering and other services
Related Party Transaction [Line Items]
Total revenue	4,456	5,801
Equity Method Investee \| Transactions with Equity Method Investees
Related Party Transaction [Line Items]
Accounts receivable	2,377		2,190
Contract Assets	606		659
Notes receivable	5,522		5,436
Accounts payable	221		$ 582
Related Party \| Licensing
Related Party Transaction [Line Items]
Total revenue	580	553
Related Party \| Engineering and other services
Related Party Transaction [Line Items]
Total revenue	$ 328	$ 420

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Nov. 09, 2022
Related Party Transaction [Line Items]
Total revenue	$ 10,244	$ 9,646
Notes receivable, commitment to purchase			$ 5,500
Sale of private placement warrants (in shares)			316,250
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 0.01
Senior Secured Notes Receivable
Related Party Transaction [Line Items]
Approval of note holders to amend agreement			66.66%
One Tranche Of Notes
Related Party Transaction [Line Items]
Sale of private placement warrants (in shares)			575,000
Amount of Notes purchased			$ 10,000
LanzaJet Freedom Pines Fuels LLC
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount			147,000
LanzaJet Freedom Pines Fuels LLC \| Senior Secured Notes Receivable
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount			$ 113,500
Line of credit facility, interest rate			6%
LanzaJet Freedom Pines Fuels LLC \| Subordinated Secured Notes Receivable
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount			$ 33,500
Line of credit facility, interest rate			6%
Related Party Transition Services Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Total revenue	31	45
Related Party Investment Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Total revenue	12	338
Deferred profit recognized	58
Related Party Supply Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Total revenue	51	0
Cost incurred	$ 185	$ 249

Commitment and Contingencies (D

Commitment and Contingencies (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Headquarters In Skokie, Illinois
Lessee, Lease, Description [Line Items]
Lease not yet commenced, liability	$ 17,216

Subsequent Events (Details)

Subsequent Events (Details) - Forecast - At Market Issuance Sales $ in Thousands	May 09, 2024 USD ($)
Subsequent Event [Line Items]
Purchase price	$ 100,000
B. Riley Securities
Subsequent Event [Line Items]
Sale of stock, daily limit	180
Sale of stock, weekly limit	900
Sale of stock, yearly limit	$ 40,000
Sale of stock, gross sales commission	3%
Sale of stock, purchase price sold, commission	5%